Sirona Biochem claims to have made a big leap in the development of skin whitening ingredients

Known as SBM-TFC-1067, or just “1067”, the compound is being developed with the aim of targeting large-scale production for the big multinational cosmetic and personal care players.

The company has relied on its own proprietary fluorination technology to enhance the processing of the compound, and this has allowed the company to simplify the processing to the point where it only take three steps to ready the ingredient.

A simple and cost effective ingredient​

The benefits of this simple and cost effective process have resulted in an ingredient that offers a higher profit margin for cosmetics companies, Sirona executives claim.

As a preliminary estimation of COGs for the active ingredient yielded CAD$0.10 per 100 ml final formulation at a final concentration of 0.1%, the company’s research and development team claims.

“Potential partners have replicated in vitro tests that we have done in the past to double-check our efficacy and safety data, and whatever else meets their needs to justify further collaboration,”​ Attila Hajdu, chief business development officer at Sirona Biochem, said.

“The request for formulation testing was a pleasant surprise for us because we originally anticipated that formulation work would occur after a licensing deal. This is a very exciting development.”​

Successful production scale-up​

The latest in the ingredient’s development story is that it has now carried out a successful scale-up of the compound, which means the company can now meet the high volume demand of larger cosmetics manufacturers.

This development has come about thanks to the work of its research partner, based in Rouen, France, a company called Roowin.

Thanks to a scientific breakthrough from this research partner, the lab has managed to develop 1kg of the compound, which has enabled it to deliver 200grams for solubility by a major multinational company under a previously signed agreement.

“Formulation testing on this quantity of compound represents a major milestone in the development of 1067, which will ultimately result in a successful licensing deal with one of the top cosmetic companies in the world. This is the first time in Sirona’s history that we have advanced a cosmetic compound to formulation testing,”​ said Dr. Howard Verrico, CEO of Sirona Biochem.